| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | STA Standard |
| ID number | 6256 |
Provisional Schedule
| Committee meeting | 12 June 2025 |
| Expected publication | 20 August 2025 |
Project Team
| Project lead | Kate Moore |
Email enquiries
- If you have any queries please email TATeam5@nice.org.uk
| External Assessment Group | School of Health and Related Research (ScHARR), University of Sheffield |
Stakeholders
| Companies sponsors | Johnson and Johnson (amivantamab, lazertinib) |
| Others | Department of Health and Social Care |
| NHS England | |
| Patient carer groups | EGFR Positive UK |
| Roy Castle Lung Cancer Foundation | |
| Professional groups | Association of Cancer Physicians |
| Association of Respiratory Nurse Specialists | |
| British Thoracic Oncology Group | |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Comparator companies | Amarox (erlotinib) - not participating |
| AstraZeneca (gefitinib, osimertinib) | |
| Boehringer Ingelheim (afatinib) - not participating | |
| Cipla EU (gefitinib) - not participating | |
| Genus Pharmaceuticals (gefitinib) - not participating | |
| Glenmark Pharmaceutical (erlotinib) - not participating | |
| Mylan (erlotinib) - not participating | |
| Pfizer (dacomitinib) - not participating | |
| Roche (erlotinib) - not participating | |
| Sandoz (erlotinib, gefitinib) - not participating | |
| Zentiva (erlotinib) - not participating | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health – Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| NHS Wales Joint Commissioning Committee | |
| Scottish Medicines Consortium | |
| Welsh Government |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 30 October 2024 | Invitation to participate |
| 23 May 2024 - 21 June 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6256 |
| 23 May 2024 | In progress. Scoping commenced. |
| 25 April 2024 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late October 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 07 February 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual